This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.


As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002
Filing Date: January 26, 2004 Serial No.:

Page 1 of 20

Customer No.: 21559






Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 2 of 20 Customer No.: 21559

Fig. 4

Fig. 5



Title: Neoplasm-Specific Polypeptides and Their Uses

Applicant(s): Müller-Hermelink et al.
Client/Matter No.: 50308/009002
Filing Date: January 26, 2004
Page 3 of 20
Custon Serial No.: Customer No.: 21559

Fig. 6





Fig. 7



Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.:

Page 4 of 20

Customer No.: 21559

Ser	tgc Cys	aag Lys	gct Al a	Ser	ġgc Gly	tac Tyr	acc Thr	ttc Phe	Thr	gac Asp	tac Tyr	tat Tyr	ata Ile	aac Asn	45	
1 tgg	gtg	aag	caq	5	act	gga	cag	gac	10	gag	taa	att	003	15	90	
Trp	Val	Lys	Gln	Arg 20	Thr	Gly	Gln	ĞÎy	Leu 25	Glu	Trp	Ile	Gly	Glu 30	90	
att Ile	tat Tyr	cct Pro	gga Gly	agt Ser 35	ggt Gly	aat Asn	act Thr	tac Tyr	tac Tyr 40	aat Asn	gag Glu	aag Lys	ttc Phe	aag Lys 45	135	
ggc Gly	aag Lys	gcc Ala	aca Thr.	ctg Leu 50	act Thr	gca Ala	gac Asp	aaa Lys	tcc Ser 55	tcc Ser	agc Ser	aca Thr	gcc Ala	tac Tyr 60	180	
atg Met	cag Glņ	ctc Leu	agc Ser	agc Ser 65	ctg Leu	aca Thr	tct Ser	gag Glu	gac Asp 70	tct Ser	gca Ala	gtc Val	tat Tyr	Phe 75	225	
tgt Cys	gca Ala	aga Arg	tcg Ser	gga Gly 80	tta Leu	cga Arg	ccc Pro	tat Tyr	gct Ala 85	atg Met	gac Asp	tac Tyr	tgg Trp	ggt Gly 90	270	
		acc Thr									•			•		

Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Customer No.: 21559

Page 5 of 20

Nucleotide sequence of the variable region of the heavy chain (VH) of antibody NM58-49/69

95

8B	
8	

		06	135	180	225	270	υ σ
	aac Asn 15	gag Glu 30	aag Lys 45	tac Tyr 60	ttc Phe 75	ggt Gly 90	
	ata Ile	gga Gly	ttc	gcc Ala	tat Tyr	tgg Trp	
CDR1	tat Tyr	att Ile	aag Lys	aca	gtc Val	tac	
S	tac Tyr	tgg Trp	gag	agc	gca Ala	J-gene tg gac et Asp	
	gac	gag Glu	aat Asn	tcc Ser	tct	atg Met	
	act Thr 10	ctt Leu 25	tac Tyr 40	tcc Ser 55	gac Asp 70	gct Ala 85	
	ttc act Phe:Thr 10	ggc Gly	Tyr	ааа Lys	gag Glu	tat Tyr	
	acc Thr	cag Gln	act	gac Asp		CDR3	
	tac Tyr	gga Gly	aat Asn	gca Ala	aca Thr	cga Arg	·
	ggc G1у	act	ggt Gly	act Thr	ctg Leu	tta Leu	acc
	Ser 5	agg Arg 20	agt Ser 35	ctg Leu S0	agc Ser 65	D-gene g gga t Gly I 80	gtc Val
	gct Ala	cag Gln	gga Gly	aca Thr	agc	t C Se 1	tca
	аад Lys	aag Lys	cct	gcc Ala	ctc Leu	aga Arg	acc
	tgc Cys	gtg Val	tat Tyr	aag Lys	cag Gln	gca Ala	gga Gly
	tcc Ser	tgg Trp	att Ile	ggc Gly	atg Met	tgt Cys	caa

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 6 of 20 Customer No.: 21559

					gtc Val										45
					agc Ser										90
					cag Gln										135
					aac Asn										180
agt Ser	Gly	agt Ser	gga Gly	tca Ser 65	999 Gly	aca Thr	gat Asp	ttc Phe	aca Thr 70	ctc	Lys	atc	agc Ser	aga Arg 75	225
					ctg Leu					Cys					270
					Phe					Lys				aaa Lys 105	315

Client/Matter No.: 50308/009002

Filing Date: January 26, 2004

Page 7 of 20

Nucleofide sequence of the variable region of the light chain (VL) of antibody NM58-49/69

Serial No.: Customer No.: 21559

4 2	06	135	180	225	270	315
tct Ser 15	tat Tyr 30	ctg Leu 45	ttc Phe 60	aga Arg 75	tca Ser 90	aaa Lys 105
atc Ile	acc Thr	ctc	agg Arg	agc aç Ser Ar 7	ggt Gly	ata Ile
tcc Ser	aac Asn	aag Lys	gac	atc Ile	caa Gln	gaa Glu
gcc Ala	gga Gly	cca Pro	CCa Pro	aag. Lys	ttt Phe	ctg Leu
Gln	aat Asn	tct Ser	gtc Val	ctc Leu	tgc Cys	aag Lys
a gat y Asp 10 CDR1	agt Ser 25	cag Gln 40	999 Gly 55	aca Thr 70	tac Tyr 85	acc Thr 100
gga Gly Cl	cat His	99c Gly	Ser	ttc	tat Tyr	999 G1y
ctt Leu	gta Val	cca Pro	ttt Phe	gat Asp	gtt Val	999 Gly
agt Ser	att	aaa Lys	cga Arg	aca Thr	99а G1у	gga Gly
gtc Val	Ser	cag Gln CDR2	aac Asn	999 61y	ctg Leu	ttc Phe
cct Pro 5	cag Gln 20	otg Leu 35	tcc Ser 50	tca Ser 65	gat Asp 80	acg Thr 95
ctg Leu	agt Ser	tac Tyr	gtt val	gga Gly	gag Glu	tac Tyr
Ser	tct Ser	tgg Trp	ааа Lys	agt Ser	gct Ala	ccg
ctc	aga	gaa Glü	tac	ggc Gly	gag Glu	gtt Val
cca Pro 1	tgc Cys	tta	atc Ile	agt Ser	gtg Val	cat

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004

Serial No.: Customer No.: 215599 Page 8 of 20

gat Asp	gtg Val	agg Arg	gag Glu	cct Pro 5	gaa Glu	aat Asn	gaa Glu	att Ile	tct Ser 10	tca Ser	gac Asp	tgc Cys	aat Asn	aiH	45
ttg Leu	t tg Leu	tgg Trp	aat Asn	tat	aag Lys	ctg Leu	aac Asn	cta Leu	act	aca Thr	gat Asp	ccc Pro	aaa Lys	ttt Phe 30	90
gaa Glu	tct Ser	gtg Val	gcc Ala	aga Arg 35	gag Glu	gtt Val	tgc Cys	aaa Lys	tct Ser 40	act Thr	ata Ile	aca Thr	gag Glu	att Ile 45	135
gaa Glu	gaa Glu	tgt Cys	gct Ala	gat Asp 50	gaa Glu	ccg Pro	gtt Val	gga .Gly	aaa Lys 55	ggt Gly	tac Tyr	atg Met	gtt Val	tcc Ser 60	180
tgc Cys	ttg Leu	gtg Val	gat Asp	cac His 65	cga Arg	ggc Gly	aac Asn	atc Ile	act Thr 70	gag Glu	tat Tyr	cag Gln	tgt Cys	cac His 75	225
cag Gln	tac Tyr	att Ile	acc Thr	aag Lys 80	atg Met	acg Thr	gcc Ala	atc Ile	att Ile 85	ttt Phe	agt Ser	gat Asp	tac Tyr	cgt Arg 90	270
tta Leu	atc Ile	tgt Cys	ggc Gly	ttc Phe 95	atg Met	gat Asp	gac Asp	tgc Cys	aaa Lys 100	aat Asn	gac Asp	atc	aac	att Ile 105	315
ctg Leu	aaa Lys	tgt Cys	ggc	agt Ser 110	att Ile	cgg Arg	ctt Leu	gga Gly	gaa Glu 115	aag Lys	gat Asp	gca Ala	cat His	tca Ser 120	360
caa Gln	ggt [.] Gly	gag Glu	gtg Val	gta Val 125	tca Ser	tgc Cys	ttg Leu	gag Glu	aaa Lys 130	ggc Gly	ctg Leu	gtg Val	aaa Lys :	gaa Glu 135	405
gca Ala	gaa Glu	gaa Glu	aga Arg	gaa Glu 140	ccc Pro	aag Lys	att Ile	caa Gln	gtt Val 145	tct Ser	gaa Glu	ctc Leu	tgc Cys	aag Lys 150	450
aaa Lys	gcc Ala	att Ile	ctc Leu	cgg Arg 155	gtg Val	gct Ala	gag Glu	ctg Leu	tca Ser 160	tcg Ser	gat Asp	gac Asp	ttt Phe	cac His 165	495
tta Leu	gac Asp	cgg Arg	Cat	tta Leu 170	tat Tyr	ttt Phe	gct Ala	tgc Cys	cga Arg 175	gat. Asp	gat Asp	cgg Arg	gag Glu	cgt Arg 180	540
ttt Phe	tgt Cys	gaa Glu	aat Asn	aca Thr 185	caa Gln	gct Ala	ggt Gly	gag Glu	ggc Gly 190	aga Arg	gtg Val	tat Tyr	aag Lys	tgc Cys 195	585
ctc Leu	ttt Phe	aac Asn	cat His	aaa Lys 200	ttt Phe	gaa Glu	gaa Glu	tcc Ser	atg Met 205	agt Ser	gaa Glu	aag Lys	tgt Cys	cga Arg 210	630

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 9 of 20 Customer No.: 21559

gaa Glu	gca Ala	ctt Leu	aca Thr	acc Thr 215	cgc Arg	caa Gln	aag Lys	ctg Leu	att Ile 220	gcc Ala	cag Gln	gat Asp	tat Tyr	aaa Lys 225		·675
			tca Ser												•	720
			aat Asn												٠.	765
			ttg Leu													810
			agc Ser													855
			atg Met		Asp											900
			G1y 999													945
			acc Thr													990
aag Lys	61y 999	aac Asn	ctt Leu	gga Gly 335	atg Met	aac Asn	tgc Cys	cag Gln	cag Gln 340	gcg Ala	ctt Leu	caa Gln	aca Thr	Leu 345		1035
										Arg				gct Ala 360		1080
										Thr				cat His 375	٠.	1125
					Pro					Cys				cat His 390		1170
			Glu							Glu				tta Leu 405		1215
					Ile					Lys				t gtc o Val 420		1260
					Gln					Arg				c acc s Thr 435		1305
cac His	ggt Gly	tgg Trp	aat Asn	gag Glu 440	Thr	agc Ser	gaa Glu	tti Phe	t atg e Met 44!	Pro	Caq Gli	9 99 n Gl	a gc y Al	t gtg a Val 450		1350
					Arg					g Thi				g gga n Gly 465		1395

Title: Neoplasm-Specific Polypeptides and Their Uses

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.:

Page 10 of 20

Customer No.: 21559

agg	agg	ctc	tca	cqq	oaq	tac	cga	act	qaa	atc	caa	agg	atc	cta	1440
															_
Arg	Arq	Leu	Ser	Arq	Glu	Cys	Arg	Ala	Glu	Val	Gln	Arq	Ile	Leu	
_	-			_		•	-					_			
				470					475					480	

cac cag cgt gcc atg gat gtc aag ctg gat cct gcc ctc cag gat 1485
His Gln Arg Ala Met Asp Val Lys Leu Asp Pro Ala Leu Gln Asp
485 490 495

aag tgc ctg att gat ctg gga aaa tgg tgc agt gag aaa aca gag
Lys Cys Leu Ile Asp Leu Gly Lys Trp Cys Ser Glu Lys Thr Glu
500 505 510

act gga cag aag ctg gag tgc ctt cag gac cat ctg gat gac tta 1575
Thr Gly Gln Lys Leu Glu Cys Leu Gln Asp His Leu Asp Asp Leu
515 520 525

gtg gtg gag tgt aga gat ata gtt ggc aac ctc act gag tta gaa 1620 Val Val Glu Cys Arg Asp Ile Val Gly Asn Leu Thr Glu Leu Glu 530 535 540

tca gag gat att caa ata gaa gcc ttg ctg atg aga gcc tgt gag
Ser Glu Asp Ile Gln Ile Glu Ala Leu Leu Met Arg Ala Cys Glu
545

ccc ata att cag aac ttc tgc cac gat gtg gca gat aac cag ata
Pro Ile Ile Gln Asn Phe Cys His Asp Val Ala Asp Asn Gln Ile
560 565 570

gac tcc ggg gac ctg atg gag tgt ctg ata cag aac aaa cac cag
Asp Ser Gly Asp Leu Met Glu Cys Leu Ile Gln Asn Lys His Gln
575 580 585

aag gac atg aac gag aag tgt gcc atc gga gtt acc cac ttc cag
Lys Asp Met Asn Glu Lys Cys Ala Ile Gly Val Thr His Phe Gln
590
595
600

ctg gtg cag atg aag gat ttt cgg ttt tct tac aag ttt aaa atg
Leu Val Gln Met Lys Asp Phe Arg Phe Ser Tyr Lys Phe Lys Met

gcc tgc aag gag gac gtg ttg aag ctt tgc cca aac ata aaa aag 1890 Ala Cys Lys Glu Asp Val Leu Lys Leu Cys Pro Asn Ile Lys Lys

aag gtg gac gtg gtg atc tgc ctg agc acg gtg cgc aat gac

1935

Lys Val Asp Val Val Ile Cys Leu Ser Thr Thr Val Arg Asn Asp

act ctg cag gaa gcc aag gag cac agg gtg tcc ctg aag tgc cgc 1980 Thr Leu Gln Glu Ala Lys Glu His Arg Val Ser Leu Lys Cys Arg 650 655 660

agg cag ctc cgt gtg gag gag ctg gag atg acg gag gac atc cgc 2025 Arg Gln Leu Arg Val Glu Glu Leu Glu Met Thr Glu Asp Ile Arg 665 670 675

ttg gag cca gat cta tac gaa gcc tgc aag agt gac atc aaa aac 2070 Leu Glu Pro Asp Leu Tyr Glu Ala Cys Lys Ser Asp Ile Lys Asn 680 685 690

ttc tgt tcc gct gtg caa tat ggc aac gct cag att atc gaa tgt
Phe Cys Ser Ala Val Gln Tyr Gly Asn Ala Gln Ile Ile Glu Cys
695 700 705

ctg aaa gaa aac aag aag cag cta agc acc cgc tgc cac caa aaa 2160 Leu Lys Glu Asn Lys Lys Gln Leu Ser Thr Arg Cys His Gln Lys 710 720

Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.:

Page 11 of 20

Customer No.: 21559

									atg Met 730						2205
tac Tyr	acc Thr	ctc Leu	atg Met	agg Arg 740	gtc Val	tgc Cys	a ag	cag Gln	atg Met 745	ata Ile	aag Lys	aag Lys	ttc Phe	tgt Cys 750	2250
			Asp						cag Gln 760					aat ' Asn 765	2295
									tgc Cys 775						2340
					Gln				tac Tyr 790						2385
					Lys				cct Pro 805	Lys					2430
					Lys				gaa Glu 820	Leu					 2475
					Leu				gac Asp 835	Gln					2520
					Ile				atc Ile 850	Gln				t Ctg Leu 855	2565
					Pro					His				gag Glu 870	2610
					Ala					Ala				aca Thr 885	2655
					Cys					Lev				aaa Lys 900	2700
					Lys					Met				a agc u Ser 915	2745
					· Val									t gcc s Ala 930	2790
					His					Thi				c 999 g Gly 945	2835
					Leu					ı Glı				g gtg g Val 960	2880
					Cys					ı Ası				t gag e Glu 975	2925

Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 12 of 20 Customer No.: 21559

		agt Ser	-	980		273	Val.	MIG	985	Ala	Asp	Gly	Phe	Ser 990		2970
		gcc Ala		995			****	ser	1000	Ser	Lys	Asn	Tyr	Ile 1005		3015
ctc Leu	tct Ser	gtg Val	atc Ile	agt Ser 1010	1	agc Ser	atc Ile	tgt Cys	ata Ile 1015	Leu	ttc Phe	ctg Leu	att Ile	ggc Gly 1020	•	3060
ctg Leu	atg Met	tgt Cys	gga Gly	cgg Arg 1025	atc Ile	acc Thr	aag Lys	cga Arg	gtg Val 1030	Thr	cga Arg	gag Glu	Leu	aag LysA 1035	-	3105
gac Asp												:				

Client/Matter No.: 50308/009002
Filing Date: January 26, 2004
Page 13 of 20
Cus Serial No.: Customer No.: 21559





Fig. 11


Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al.
Client/Matter No.: 50308/009002
Filing Date: January 26, 2004 Serial No.:
Page 14 of 20 Customer No.: 21559




Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.: Page 15 of 20 Customer No.: 21559






Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 16 of 20 Customer No.: 21559



Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Page 17 of 20 Customer No.: 21559



Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004 Serial No.: Customer No.: 21559 Page 18 of 20

								•				
	PFPAGGPP-R PFPAGGPPAR	ADEPVGKGYN ADEPVGKGYN ADEPVGKGYN	CKKAILRVAE CKKAILRVAE CKKAILRVAE	PRSREARLSY PRSREARLSY PRSREARLSY	TDPGADYRID TDPGADYRID TDPGADYRID	AVFSCLYRIFA AVFSCLYRFA AVFSCLYRHA	LLMRACEPII LLMRACEPII LLMRACEPII	eakehrvslk Eakehgvslk Eakeervslk	FCPEADSKTM FCPEADSKTM FCPEADSKTM	IIQESALDYR IIQESALDYR IIQESALDYR	SCLMEALEDK SCLMEALEDK SCLMEALEDK	
	00000000000000000000000000000000000000	KSTITEIESC KSTITEIKEC KSTITEIKEC	REPKIQVSEL REPKIQVSEL REPKIQVSEL	KKYRCNVENL KKYRCNVENL KKYRCNVENL	QQALQTLIQE QQALQTLIQE QQALQTLIQE	NETSEKKPOG NETSEKMPOG KETSEKMPOG	lesediqiea Lesediqiea Lesediqiea	STTVRNDTLQ STTVRNDTLQ STTVRNDTLQ	ARVCKQMIKR FCPEADSKTM ARVCKQMIKR FCPEADSKTM MRVCKQMIKR FCPEADSKTM	SSOCEDQIRI SSOCEDQIRI SSDCEDQIRI	aitpgrgrom altpgrgrom aitpgrgrom	
	00000000710	KFESVAREVC KFESVAREVC KFESVAREVC	ekglvkeaee ekglvkeaee ekglvkeaee	SLAKSCKSDL SLAKSCKSDL SLAKSĆKSDL			CRDIVGNLTE CRDIVGNLTE CRDIVGNLTE	KKKVDVVICL KKKVDVVICL KKKVDVVICL	NMDPELOYTL NMDPELOYTL NMDPELDYTL	LKLRYADQRL LKLRYADQRL LKLAYADQRL	IFVDPVLHTA CALDIKHHCA AITPGRGROM IFVDPVLHTA CALDIKHHCA ALTPGRGROM IFVDPVLHTA CALDIKHHCA AITPGRGROM	RVTRELKDR* RVTRELKDR* RV:RELKDR*
	QQLPQL1QSS QQLPQL1QSS	NYKLHLTTD? NYKLNLTTD? NYKLNLTTD?		LIAQDYKVSY LIAQDYKVSY LIAQDYKVSY	TLHCLMKVVR GEKGNLGHNC TLHCLMKVVR GEKGNLGHNC TLHCLMKVVR GEKGNLGHNC	PVLYRKCQGD ASRLCHTHGW FVLYRKCQGD ASRLCHTHGW PVLYRKCQGD ASRLCHTHGW	QDIILJOLVVE QDHLDJLVVE QDHLDOLVVE	EDVLKJCPNI EDVLKJCPNI EDVLKLCPNI	QKVFKLQETE QKV FKLQETE QKVFKLQETE	SELEGQVISC LKLRYADORL SELEGGVISC LKLRYADORL SELEGOVISC LKLRYADORL	IFVDPVLHTA CALDIKHHCA IFVDPVLHTA CALDIKHHCA IFVDPVLHTA CALDIKHHCA	IGLMCGRITK RVTRELKDR* IGLMCGRITK RVTRELKDR* IGLMCGRITK RVTRELKOR*
	GOAGGGGPAG	ISSDCHHLLW ISSDCHHLLW ISSDCHHLLW	GSIRLGEKDA HSGGEVVSCL GSIRLGEKDA HSGGEVVSCL GSIRLGEKDA HSGGEVVSCL	CREALTTROK CREALTTROK CREALTTROK	HCSGLHRKGR HCSGLHRKGR HCSGLHRKGR	YFISROWKLD YFISROWKLD YFISROWKLD	TETCOKLECL TETCOELECL ILHORAMDVK	esykermack esykermack esykermack	nkkolstrch nkkolstrch nkkolstrcii	HGILTKAKDD HGILTKAKDD HGILTKAKDD	IKTELCKKEV LNMLKESKAD IKTELCKKEV LNMLKESKAD IKTELCKKEV LNMLKESKAD	ISGS_CILFL IGLMCGRITK ISGS_CILFL IGLMCGRITK ISGS_CILFL IGLMCGRITK
	GPGANFVSFV GPGANFVSFV	DVREPENE LODVREPENE LOOVREPENE	CKNDINITKC CKNDINITKC CKNDINITKC	EGRVYKOLEN HKFEESMSEX EGRVYKOLEN HKFEESMSEX EGRVYKOLEN HKFEESMSEK	ILSCRGEIEH ILSCRGEIEH ILSCRGEIEH	DCEHRLLELO DCEHRLLELO DCEHRLLELO	IDLGKWCSEK IDLGKWCSEK SRECRAEVQR	golvomkder Folvomkder Folvomkder	NAQIIECLKE NAQIIECLKE NAQIIECLKE	ACKADIPKFC ACKADIPKFC ACKADIPKFC	IKTELCKKEV IKTELCKKEV IKTELCKKEV	SPSKNYILSV SPSKNYILSV SPSKNYILSV
i *	PARASHSOGC PGHGVHSQGO	WSNNLAVLEC	YRLICGFMDD YRLICGFMDD YRLICGFMDD	EGRVYKCLEN HKFEESMSEK EGRVYKCLEN HKFEESMSEK EGRVYKCLEN HKFEESMSEK	MEDFSLSPEI MEDFSLSPEI MEDFSLSPEI	EHLYTEKMVE EHLYTEKMVE EHLYTEKMVE	LOPALQDKCL LOPALQDKCL TETGQELECL	NEKCAIGVTH NEKCAIGVTH NEKCAIGVTH	KNFCSAVQYG KNFCSAVQYG KNFCSAVQYG	DYRLNPMLRK DYRLNPMLRK DYRLNPMLRK	EECLKVNLLK SECLKVNLLK SECLKVNLLK	ssolamovnt Fsolamovnt Fsolamovnt
	LLFRAGGRNS LLFRAGAEKL	DVTRVCPXHT DVTRVCPKIIT	TKMTALLESD TKMTALLESD TKMTALLESD	erfcentoag erfcentoag erfcentoag	GENLDYRRML GENLDYRRML GEMLDYRRML	GDPMILSCLM GDPMISSCLM GDPMILSCLM	ILHÜRAMDVK ILHÜRAMDVK IDLGKWCSEK	LIQNKHOKDM LIQNXHOKDM LIQNXHOKDM	DLYEACKSDI DLYEACKSDİ DI.YEACKSDI	ITKROITONT ITKROITONT ITKROITONT	AAAQEQTGQV AAAQEQTGQV AAAQEQTGQV	YAAKVAPADG YAAKVAPADG YAAKVAPADG
	FRESABHIL FRESAALHIL	KLAEEESCRE	ITEYQCHQYI ITEYQCHQYI ITEYQCHQYI	IILY FACRODR IILY FACRODR HI.Y FACRODR	KGRQVSSECQ KGRQVSSECQ RGRQVSSECQ	IQTACKHIRS IQTACKHIRS IQTACKHIRS	SRECRAEVOR SAECRAEVOR LDPALODECL	OIDSCOLMEC CIDSCOLMEC	EMTEDIRLEP EMTEDIALRP EMTEDIRL3P	SLMDPKCKOM SLMDPKCKOM SLMDPKCKOM	DEISSLCAEE DEISSLCAEE DEISSLCAEE	ALNORIEMWS RLNORIEMWS RLNORIEMWS
	MAACGEVERM	RSGAGAGGGW RSGAGAGAGGGW	VSCLVDHRGN VSCLVDHRGN VSCLVDHRGN	LSSJDFHLÖR LSSJUFHLOR LSSDJYHLUR	LLMCLESAVH LLMCLESAVH LLMCLESAVH	RALNEACESV RALNEACESV RALNEACESV	YRTEEQGRRU YRTEEQGRRU YRTEEQGRRL	QNFCHDVADN QTFCED-ADN	CRRCLRVSEL CRRCLRVSEL CRRCLRVSEL	LQCLKQNKNS B LQCLKQNKNS B LQCLKQNKNS B	LOPQLQLHCS LOPQLQLHCS LOPQLQLHCS	RVALQPECKK RVALQPECKK RVALQPECKK
			201	301	100	501 501 501	601	701	801 801	901	1001	1101
:	23132 CFR-1 MG160	23132 CFR-1 MG160	23132 CFR-1 MGL 60	23132 CFR-: MG160	23132 CFR-1 MG165	23132 CFR-1 MG160	23132 . CFR-1	23132 CFR-1	23132 CFR-1 KG160	23132 CFR-1 MG160	23132 CFR-1 MG: 60	23132 CER :1 NG160

Heavy chain sequence CDR I AGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT GGC 54 Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Gly 10 ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTA GTT ATA 108 Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Val Ile CDR II TCA TAT GAT GGA AGT AAT AAA TAC TAT GCA GAC TCC GTG AAG GGC CGA TTC ACC 162 Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr 40 45 ATC TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA 216 Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg 65 CDR III GCT GAG GAC ACG GCT GTG TAT TAC TGT GCG AGG TCG ACT ACG AGG TCT TAT CCT 270 Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Thr Arg Ser Tyr Pro 80 85 CDR III CTA TAC GGT ATG GAC GTT TGG GGC CAA GGG AAC CCT GTC ACC 312

Title: Neoplasm-Specific Polypeptides and Their Uses

Human antibody PAM-1 (clone 103/51)

Serial No.:

Customer No.: 21559

Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002 Filing Date: January 26, 2004

Page 19 of 20

Leu Tyr Gly Met Asp Val Trp Gly Gln Gly Asn Pro Val Thr

Fig. 17

Title: Neoplasm-Specific Polypeptides and Their Uses Applicant(s): Müller-Hermelink et al. Client/Matter No.: 50308/009002

Filing Date: January 26, 2004 Serial No.:
Page 20 of 20 Customer No.: 21559

Human antibody PAM-1 (clone 103/51)

Light chain sequence

								Ser		GCC Ala 15	Pro			54
										AGT Ser				108
										(CDR :	ΙΙ		
										GAT Asp				162
										GGG Gly				216
										TAT Tyr			CAG Gln 90	270
		CD	R II	I										
										AGG Arg 105				324
										GTT Val				378
	AGC Ser 130				399	e	-							

Fig. 18